First Tracks reports positive ANB033 celiac disease results
First Tracks Biotherapeutics reported a statistically significant protective effect for ANB033 in a phase 1b celiac study, with no safety signals.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Reuters reported that First Tracks Biotherapeutics released positive top-line results from a gluten-challenge study of ANB033 in patients with celiac disease. In the phase 1b trial, the drug produced a statistically significant protective effect, with a placebo-adjusted delta of +0.49 in the VH:CD ratio at week 6 and P=0.009.
The company said ANB033 was well tolerated and that no safety signals had been observed to date. Top-line results from cohort 2 of the phase 1b celiac disease trial are expected in Q1 2027, while data from the phase 1b cohort in eosinophilic esophagitis are expected in Q3 2027.
First Tracks also plans to begin phase 2 development of ANB033 in vitiligo and an additional indication in H1 2027.
why it matters
The results may affect market views of First Tracks’ clinical development program. Their longer-term significance will depend on data from the remaining cohorts and subsequent development stages.
instruments
sources
- First Tracks Biotherapeutics Announces Positive Top-Line Results For ANB033 In Gluten-Challenge Study In Celiac Disease — Reuters, 12 October 2026 at 11:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗